
ABOUT IDT BIOLOGIKA
WITH PASSION WE BRING PHARMACEUTICAL SOLUTIONS TO LIFE.
IDT Biologika is a global biopharmaceutical contract development and manufacturing organization (CDMO) specializing in vaccines, gene and immune therapeutics, and the fill-finish of other sterile injectables. With decades of experience across various vaccine platforms, we integrate cutting-edge innovations in advanced therapies and our expertise in fill-finish to provide tailored solutions that support our customers in advancing their products.
Our end-to-end services include process development, drug substance manufacturing, sterile dosage filling, labeling, packaging and quality control. All analytical services are performed in-house. From early-stage development to clinical and commercial manufacturing, we ensure seamless integration at every step, delivering flexibility, regulatory compliance, and the highest quality standards. Our commitment to operational excellence is reflected in our best-in-class process and GMP manufacturing, meeting FDA, EMA and ANVISA standards.
Driven by passion, innovation, and a commitment to excellence, we strive to make a meaningful impact on global healthcare by helping our customers bring their products to market.
VIDEOS
CONTACT INFORMATION
IDT Biologika
Dessau-Rosslau, Germany
US Sales Office, USA
Phone: + 1 951 719 9718
Contact: Lifeng He, IDT Biologika
BROCHURES AND SERVICES
ARTICLES
NEWS
- IDT Biologika Appoints Federico Pollano As New Chief Commercial Officer
- IDT Biologika Receives CDMO Leadership Awards 2024 In Six Categories
- IDT Biologika Collaborates With CanVirex To Push Forward The Treatment Of Cancer
- IDT Biologika Receives CDMO Leadership Awards 2023 in Five Categories
- IDT Biologika With New Dual Leadership: Dr. Ulrich Valley Appointed Second Managing Director
- IDT Biologika Receives CMO Leadership Awards 2022 In Six Categories
- IDT Biologika Is Increasing Its Production Capacity Of Vaccines, Saxony-Anhalt's Prime Minister Reiner Haseloff Visited The New Facilities
- Valneva And IDT Biologika Announce Collaboration For Production Of Inactivated COVID-19 Vaccine VLA2001
- IDT Biologika And Takeda Support Production Of The Johnson & Johnson Single-Shot COVID-19 Vaccine
- IDT Biologika To Receive Funding For The Clinical Trials Of Phases I To III And The Application For COVID-19 Vaccine Approval
- SARS-CoV-2: IDT Biologika Fills Vaccine Candidate - Clinical Phase About To Begin